Zhifei Biological wins approval for CA111 injection clinical trials

Chongqing Zhifei Biological Products Co. (Zhifei Biological) announced that its holding subsidiary, Chongqing Chen'an Bio-Pharmaceutical Co., has received approval from the National Medical Products Administration for clinical trials of CA111 injection. The approvals permit the initiation of clinical trials in adult patients who are overweight or obese.

CA111 injection is an innovative, Class 1 chemical drug developed by Chen'an Bio-Pharmaceutical. It acts as a dual agonist for glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The company holds effective invention patents for the molecular structure and use of CA111, with promising market prospects in diabetes and weight loss treatment.

Zhifei Biological emphasized that this development will strengthen its "prevention & treatment" layout and enhance pipeline synergy, contributing to sustainable growth. As of the announcement date, only tirzepatide injection has been approved for market in China, with no other domestic products targeting the same receptors having received market approval yet.